Liposomal Amphotericin B Injectable Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg/vial
Reference Brands: AmBisome(US & EU)
Category:
Anti-fungal
Liposomal Amphotericin B binds to fungal ergosterol, creating pores that disrupt cell membrane integrity and cause fungal cell death. It offers broad-spectrum activity, enhanced tissue penetration, and reduced toxicity compared to conventional formulations. Benefits include effective treatment of severe systemic infections with fewer side effects, improving patient outcomes.
Liposomal Amphotericin B Injectable is available in Injection
and strengths such as 50 mg/vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Liposomal Amphotericin B Injectable is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Liposomal Amphotericin B Injectable can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Liposomal Amphotericin B is approved in the EU and US for severe fungal infections. In the EU, Gilead’s AmBisome is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, FDA-approved AmBisome is backed by comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and submissions, visit PharmaTradz. We facilitate efficient market access for Liposomal Amphotericin B, ensuring adherence to European and American standards for safe, effective antifungal therapy, reducing toxicity while maintaining efficacy in severe infections.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing